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The accumulating evidence demonstrates the essential role of neuregulin-1 signaling in the adult heart, and, moreover, indicates
that an impaired neuregulin signaling exacerbates the doxorubicin-mediated cardiac toxicity. Despite this strong data, the specific
cardiomyocyte targets of the active erbB2/erbB4 heterodimer remain unknown. In this paper, we examined pathways involved in
cardiomyocyte damage as a result of the cardiac sensitization to anthracycline toxicity in the ventricular muscle-specific erbB4
knockout mouse. We performed morphological analyses to evaluate the ventricular remodeling and employed a cDNA microarray
to assess the characteristic gene expression profile, verified data by real-time RT-PCR, and then grouped into functional categories
and pathways. We confirm the upregulation of genes related to the classical signature of a hypertrophic response, implicating an
erbB2-dependent mechanism in doxorubicin-treated erbB4-KO hearts. Our results indicate the remarkable downregulation of
IGF-I/PI-30 kinase pathway and extends our current knowledge by uncovering an altered ubiquitin-proteasome system leading to
cardiomyocyte autophagic vacuolization.
1. Introduction
Overexpression of erbB2 oncogene in breast cancer cells
is indicative of highly proliferative tumors with a poor
prognosis following conventional chemotherapy [1]. Com-
bined therapy of anthracycline derivatives and antibodies
against erbB2 (i.e., trastuzumab, Herceptin) is clinically
effective with objective tumor regressions and lower rates
of both recurrence and mortality of breast cancer patients
relatively resistant to tamoxifen [2, 3]. However, an undesired
effect of this therapy is the severe dilated cardiomyopathy
manifested in a subpopulation of treated patients. The
synergistic cardiotoxicity of the combined therapy results
in a 30% incidence of cardiac dilation compared to the
1–5% registered in patients receiving either trastuzumab
or anthrayclines alone. Long-term retrospective analyses of
trastuzumab suggest that an impaired neuregulin-1 (NRG-1)
signaling sensitizes the heart towards a toxic response, that is,
to anthracycline derivatives [3].
Murine models harboring mutations in any component
of the NRG-1 signaling through tyrosine kinase receptors
erbB2 and erbB4 have demonstrated that this pathway is
critical for cardiac development and the maintenance of
proper adult heart remodeling and function. Conditional
deletion of either erbB2 or erbB4 receptors in ventricular
muscle leads to dilated cardiomyopathy in adult mice [4–
6]. Despite the evidence on the essential role of NRG-
1 signaling in the adult heart, the specific cardiomyocyte
targets of the active erbB2/erbB4 heterodimer remain
unknown.
The subcellular localization of both erbB2 and erbB4
proteins to the T-tubule membrane system [5, 6] may
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provide functional clues as integrators of environmental
signals active in the maintenance of cardiac structure, as well
this accumulation into precise sites of the cardiomyocyte
membrane may facilitate the exposure to trastuzumab,
contributing to the cardiotoxic effects in human patients.
In agreement with the hypothesis that an NRG-1-
deficiency provides the substrate for the aggravated doxoru-
bicin cardiotoxicity with a net result in cardiomyocyte dam-
age, we searched for molecular pathways which expression
and activities were exacerbated in the doxorubicin-treated
erbB4-KO. Therefore, this study focused on the remodeling
nature and on the molecular bases of cardiomyocyte loss in
the doxorubicin-treated erbB4-KO.
We employed histological and immunochemical assays to
identify the morphological changes and a cDNA microarray
to assess the gene expression profile in the three models of
dilated cardiomyopathy utilized: ventricular muscle-specific
erbB4 knockout (erbB4-KO), doxorubicin-treated wildtype
(WTD), and erbB4-KO (erbB4-KOD). Gene expression
data was verified by real-time RT-PCR, and then clus-
tered into functional categories. The aggravated condition
of doxorubicin-treated erbB4-KO hearts resulted in the
hypertrophic enlargement of cardiac chambers, which may
involve erbB2-mediated mechanisms. This study extends
our current knowledge by uncovering the downregulation
of IGF-I/PI30-Kinase complex with the altered activity of
the ubiquitin-proteasome system in cardiomyocytes, lead-
ing to an abnormal protein homeostasis with significant
autophagic vacuolization.
2. Materials and Methods
2.1. Breeding and Analysis of erbB4 Gene-Targeted Mice.
All experimental protocols were approved by the CICUAL
(commission for care and use of laboratory animal) at
the University of Buenos Aires, in accordance with the
National Institutes of Health “Guide for the Care and Use of
Laboratory Animals” (US DHHS Publication number 85-23,
Revised 1996).
The erbB4F/F mice C57Bl/6 were crossed into
erbB4+/−:MLC2vCreKI+/− mice and maintained in
colonies. The genotype of individual mouse was determined
by PCR on tail DNA. The expression of erbB4 WT-, and
recombined alleles was also verified in a subgroup of animals
by RT-PCR (data not shown) using primers corresponding
to exons 1 and 4 of erbB4 cDNA as previously described [6].
2.2. Doxorubicin Treatment. Isogenic, sex and age matched
wildtype and knockout littermates of C57Bl/6 background
were treated with doxorubicin at a final concentration
of 15 mg/kg for a week. The treatment consisted of 3
intraperitoneal injections administered in 3 alternate days
and left for 2 days prior to sacrifice to achieve sublethal
cardiotoxicity [7, 8].
2.3. Histochemical and Morphological Analyses. Dissected
hearts from male mice were washed in saline phosphate
buffer. Hearts were fixed in 4% buffered paraformaldehyde
and embedded in paraffin. Paraffin-embedded 5-μm-thick
serial tissue sections were rehydrated and stained with hema-
toxylin and eosin. The morphometric analysis of cardiomy-
ocytes was performed in individual myocytes isolated using
an alkaline dissociation method based on formaldehyde-
fixed-ventricles treated with 12.5 N KOH for 24 hs [6].
Apoptosis was monitored by TdT-mediated dUTP nick end
labeling TUNEL reaction (Intergen, Burlington, MA) in 5-
μm-thick serial tissue sections. Western blots were employed
with antibodies against caspase 3 and anti-GAPDH (Santa
Cruz Biotech, Santa Cruz, CA). Immunohistochemical anal-
yses were performed in 5-μm tissue sections by indirect
immunostaining using antibodies against ubiquitin (Dako,
Denmark). Cell membrane was counterstained with wheat
germ agglutinin coupled to fluorescent probe 555 (Invitro-
gen, Carlsbad, CA) and nuclei with DAPI (Vectashield, Vec-
tor labs, Burligame, CA). Primary antibodies were detected
by fluorescent labeling with biotin-coupled antibodies and
streptavidin-FITC (Amersham, GE Healthcare Bioscience,
NJ), as previously described [6]. Immunostained sections
were analyzed by fluorescent and confocal microscopy
(Zeiss, Oberkochen, Germany). Cardiomyocytes with large
ubiquitin-protein aggregates were counted in 40 consecutive
fields in alternate tissue sections containing both cardiac half
to the base and to the apex.
Cellular release of cardiac troponin I (cTnI) was deter-
mined in serum, utilizing a cTnI ELISA kit according to
the protocol provided by the manufacture (Access Accu TnI
number 33340, Beckman Coulter Diagnostic Division, CA).
Each experiment was performed in duplicates of at
least 4 different biological samples from each of the three
pathological conditions and WT. Statistical significance
between groups was analyzed by ANOVA and Student’s t-
test.
2.4. Contractility Determination. Isolated hearts from sex
matched 3-month-old WT (n = 4), WTD, (n = 4), erbB4-
KO (n = 4) and erbB4-KOD (n = 4) isogenic C57/Bl6
mice, were perfused according to the Langendorff technique
at constant temperature (37◦C), flow (3-4 mL/min), and
heart rate (360 beats/min), as previously described [9]. The
basal mechanical data obtained in erbB4-KO and erbB4-
KOD mice were compared to WT and WTD mice of
the same littermate. The mechanical activity was assessed
through an intracardiac water-filled latex balloon connected
to a pressure transducer (Perceptor disponsable transducer,
Namic), achieving a left ventricular end-diastolic pressure
of 5–10 mmHg. Left ventricular contractile performance was
evaluated from the developed pressure (LVDP) and from the
half-relaxation time (t1/2). The response to isoproterenol
(300 nM) was determined as the left ventricular developed
pressure (LVDP).
2.5. cDNA Microarray. For reverse transcription (Super-
script III, Invitrogen) in the presence of cyanine-coupled
deoxycytidine triphosphate (dCTP; Cy3 or Cy5; Amer-
sham Bioscience), 20 μg of total RNA were used in a
30-μL reaction. Labeled complementary DNAs (cDNAs)
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were combined with 380 μL TE (10 mM Tris, 1 mM
ethylenediamine tetracetic acid), 20 μg mouse or human
Cot1 DNA and 20 μg Oligo(dA), and purified with a
Microcon YM-30 column (Millipore, Billerica, MA). Sam-
ples were vacuum-centrifuged and resuspended in 7.5-
μL nuclease-free water, 2.5-μL deposition control targets
(Agilent Technologies), and 15-μL DIG hybridization buffer
(Roche Diagnostics, Indianapolis, IN). Denatured sam-
ples (98◦C, 2 min) were hybridized on cDNA microarrays
(G4104A, Agilent) in a humidified chamber at 42◦C for
15 h. Four technical replicates with pooled samples were
carried out for each mouse line using exchanged dye-
labeled RNA probes (dye-swap). After washing, microar-
ray slides were scanned using a microarray scanner
(G2565BA, Agilent) and image analysis was performed
with the Feature Extraction software 7.1.1 (Agilent). Func-
tional gene annotation, classification, and pathway analysis
was performed by gene ontology terms. David software
(http://david.abcc.ncifcrf.gov/) was also employed, and con-
necting networks was approached with ingenuity software
(http://www.ingenuity.org/). The gene expression data were
deposited in the Gene Expression Omnibus (GEO) database
(http://www.ncbi.nlm.nih.gov/projects/geo/) as GEO acces-
sion GSE17749.
For the identification of differentially expressed genes in
the comparison of two conditions with microarrays we used
the significance analysis of microarrays (SAM) [10]. The
SAM statistic identifies significant changes in gene expression
by performing a set of gene-specific tests. For each gene,
a score is calculated on the basis of the expression change
relative to the standard deviation of repeated measurements
for that gene. Genes with scores greater than a threshold delta
were defined as significantly deregulated. Manual adjustment
of this threshold delta allows the identification of smaller
or larger gene cohorts. In addition, scores for random
permutations of all measurements were calculated as well
and based on the defined threshold delta a false discovery rate
(FDR) was estimated.
3. Results
3.1. Murine Model for Doxorubicin-Mediated Toxicity in a
Background of Impaired Neuregulin Signaling. The cardiac
sensitization of an impaired NRG-1 signaling to the exac-
erbated anthracycline toxicity was comparatively assessed
by doxorubicin treatment of the ventricular-specific erbB4
knockout mouse. Therefore, both wildtype (WT) and erbB4-
KO mice were treated with doxorubicin (15 mg/kg), sub-
sequently named WTD and KOD, respectively. Mice were
IP injected with 3 subdoses of doxorubicin (5 mg/kg) in
three alternate days within a week at two stages of postnatal
development: young adults at the age of 1 month, prior to
ventricular dilation, and adult erbB4-KO mice at the age
of 3 months. The successive administration of doxorubicin
achieved a cardiotoxicity manifested by the thinning of
ventricular walls at both 1 and 3 months of age in WT and
KO with the overt enlargement of the ventricular chambers






Figure 1: Doxorubicin exacerbates ventricular dilation in
adult erbB4-KO hearts. Hematoxilin-eosin stained longitudinal
and transverse ventricular sections from doxorubicin-treated
(a) 1-month young adult erbB4F/F:MLC2v+/+ (WTD), and
erbB4F/F:MLC2v-Cre+/− (erbB4-KOD) mice and (b) 3-months
adult WTD and erbB4-KOD mice display exacerbated ventricular
dilation. Dilation of both RV and LV is noted in the doxorubicin-
treated at the age of 1 month erbB4-KO hearts. Aggravated dilation
was monitored at the age of 3 months. Scale bar: 1 mm.
3.2. Remodeling of Cardiomyocytes. Doxorubicin mediated
a significant increase in heart-to-body weight ratios in the
knockouts with an average of 6.2± 0.8 mg/g at 1 month and
of 6.7 ± 0.8 mg/g at 3 months of age with no significant
differences in body weight among the three conditions and
WT mice (Table 1 ), which is consistent with a hypertrophic
remodeling.
The cardiomyocyte remodeling was morphologically
addressed by the monitoring of the cell length in
KOH-isolated cardiomyocytes. In young adult mice, the
doxorubicin-induced remodeling was marked by abnormally
elongated cells of 137 μm ± 21 μm in KOD versus 100 μm ±
4 μm in WTD. In adult mice, doxorubicin treatment resulted
in a heterogeneous cell population with 42% of abnormally
elongated myocytes of 174 ± 55 μm in WTD and with 65%
of cells of 208 ± 65 μm in KOD (Table 1).
The contractile function was determined in isolated
hearts of WTD and KOD with a lower left developed
pressure (LVDP) relative to the corresponding non-treated
WT and KO hearts (Figure 2). The LVDP of erbB4-KOD
hearts reached a 40% of WTD of the same littermate,
which is similar to the nontreated KO versus Wt ratio. The
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Table 1: Doxorubicin-mediated cardiomyocyte phenotypic modifications. Heart weight and body weight were monitored in WT, WTD,
erbB4-KO, and KOD (n = 20) at 1 and 3 months of age. Hypertrophic growth is indicated by the increase in heart-body-weight ratio in
erbB4-KO and KOD compared to WT and WTD. Cell length was determined in isolated cardiomyocytes from hearts of 1 and 3 months of
age (n = 4). The length average was increased in young adult KOD. The average over 129 μm long was increased in KO, WTD, and KOD
compared to WT hearts. Values are means ± SD; Data changes were statistically compared to WT, #P < 0.05; ∗P < 0.01.
Morphology WT KO WTD KOD
Young Adult (1 month)
Heart/Body weight (mg/g) 5.2 ± 0.4 5.3 ± 0.6 5.2 ± 0.5 6.2 ± 0.8#
Body weight (g) 17.4 ± 2.0 17.3 ± 2.2 17.3 ± 2.0 17.2 ± 1.5
Average cell length > 90 μm 95 ± 10 102 ± 8 100 ± 4 137 ± 21#
Adult (3 month)
Heart/Body weight (mg/g) 5.6 ± 0.6 7.3 ± 0.8∗ 5.4 ± 0.7 6.7 ± 0.8
Body weight (g) 30.1 ± 2.5 30.3 ± 2.2 29.4 ± 2.2 28.4 ± 2.2
Average cell length > 129 μm, (%) 152 ± 14 (15) 195 ± 50∗ (75) 174 ± 57# (42) 208 ± 58∗ (65)
∗
P < 0.01, #P < 0.05.
inotropic response to beta-adrenergic agonists was preserved
in doxorubicin-treated mice with a significant increase in
LVDP (Figure 2). Doxorubicin-treated mice displayed simi-
lar and statistically significant relaxation parameters relative
to nontreated mice as monitored by the half relaxation time,
t1/2 ratios.
3.3. Gene Expression Profile. The remodeling of the ven-
tricular chambers is linked to changes in gene expression
involved in a panel of physiopathological conditions from
hypertrophy and dilation to heart failure [11–13]. The
search for differentially deregulated set of genes in dilated
cardiomyopathy was performed by comparing the transcript
levels from adult erbB4-KO, WTD and KOD relative to WT
mouse hearts in hybridization experiments in microarrays
containing over 8,500 mouse cDNA clones.
The significant expression changes in set of genes identi-
fied in the three mouse conditions by cDNA microarray data
analysis was verified with quantitative RT-PCR (Figure 3) in
mRNA samples from male and female ventricles of 1 and
3 months of age. The gene expression level determined by
quantitative RT-PCR (qRT-PCR) within individual samples
was normalized against GAPDH mRNA, and compared to
microarray ratios. The high consistency in the correlation
of the array value ratios and the qRT-PCR ratios (r : 0.83)
demonstrated the high fidelity of the microarray analysis to
detect gene expression changes (Figure 3(a)).
To interpret the list of genes, we performed a com-
putational analysis for enrichment of gene ontology (GO)
terms [14]. Among the top functionally toxic or disease
groups, a large set of genes were associated to hypertro-
phy, necrosis/cell death, cardiac damage, and dilation. The
hypertrophic group of genes prevailed in the knockouts
(KO, KOD) over other classifications, this group was less
represented in WTD hearts, which was underlined by a
general cell death group (Figure 3(b)).
To investigate molecular targets and pathways implicated
in the exacerbated cardiotoxic phenotype, we performed
gene clustering and pathway analyses to get insight into
severely modified functional groups that may account for
the sensitize condition of erbB4-KO hearts to doxorubicin
toxicity.
3.4. Commonality in Gene Expression Profile
3.4.1. Hypertrophy-Related Genes. The heart of all three
mouse models showed the classical signature of a hyper-
trophic response by the upregulation of BNP (Nppb), CARP
(Ankrp), skeletal muscle-actin, c-fos, LIM domain proteins,
and cyclin-dependent kinase inhibitor 1A, p21 (cdkn1a).
However, a hallmark of hypertrophy-related genes, the atrial
natriuretic peptide (Nppa), was found slightly increased in
WTD hearts compared to the high ratios determined in the
KO, with intermediate ratios in KOD (Table 2).
3.4.2. Hypertrophy-Related Mechanisms. The functional
clustering of large set of genes allowed for the search
of mechanisms leading to hypertrophy. This analysis
positioned a cohort of mediators, including the upregulation
of heparin binding-epidermal growth factor (Hb-egf ),
cdkn1a, Ankrp, Serum/glucocorticoid kinase (Srgk), G
protein-coupled receptor kinase 5 (Gprck5), and Gadd45g, in
an erbB2-dependent hypertrophic signaling (Table 2), with
a higher number of significantly deregulated genes in KOD
relative to WTD and KO.
3.5. Cell Cycle in Hypertrophic Remodeling. The reduction
in cell proliferation in the three conditions was indicated
by deregulation of cell-cycle-associated genes (Table 2). The
decreased level of mitosin, cyclins, and cyclin-dependent
kinase messenger RNA were accompanied by the increased
expression of the antiproliferative cyclin-dependent kinase
inhibitor 1A (p21), also upregulated in other models of
cardiomyopathy [11, 12].
3.6. Cell Survival and Apoptosis. Cell survival and stress-
related genes Bcl-2 and Bcl-2-like (Bcl2l1) were slightly
upregulated in the knockouts, with no changes in pro-
apoptotic genes (Bax, Fas, FasL) as monitored by qRT-PCR.
The expression of apoptotic-related genes, that is, Gadd45g
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Table 2: Commonality in set of genes related to hypertrophy and cell cycle. Differentially expressed set of genes verified by real-time RT-
PCR. Representative genes associated with hypertrophy, and related to erbB2-dependent hypertrophic signaling, were found significantly
upregulated in the three conditions. Cell cycle genes were preferentially downregulated with overexpression of Cdck1a. Data was normalized
to glyceraldehyde 3-phosphate dehydrogenase (Gapdh) expression and to WT. Data are expressed as mean value ratios at FDR < 10
significance, ns: not significant.
Gene
ErbB4-KO WTD ErbB4-KOD
Ratio FDR Ratio FDR Ratio FDR
Hypertrophy
actin, alpha, skeletal muscle (acta1) 2.7 1.7 1.2 ns 1.7 5.4
cardiac ankyrin repeat protein (Carp) 6.1 1.7 2 0.6 2.4 1.5
matrix gamma carboxyglutamate protein (mglap) 2.2 5.1 1.5 3.9 1.7 1.5
four and a half LIM domains 1 (fhl1) 3.3 1.7 1.8 1.3 6 6.1
natriuretic peptide precursor A (nppa) 5.9 1.7 1.4 7.8 2.9 3.3
natriuretic peptide precursor B (nppb) 6.1 1.7 8.3 0.6 6.3 1.5
cardiomyopathy associated 1 (Cmya1) 1.1 ns 3.1 0.6 2.4 2
Hypertrophic erbB2-signaling
Heparin binding epidermal growth factor (Hbegf) 1.4 n.s 4.6 0.6 4.5 14.7
Fibrinogen-like protein 2 (Fgl2) 2.0 1.6 1.0 ns 6.0 0.1
Cyclin-dependent kinase inhibitor 1A (cdnk1a) 2.3 1.6 3.0 0.6 2.7 0.1
Ankyrin-like repeat protein (Ankrd) 6.1 1.7 2.0 0.6 2.6 0.1
Myelocytomatosis oncogene (Myc) 1.5 21.1 2.9 0.6 1.7 0.2
FBJ osteosarcoma oncogene (Fos) 2.0 1.7 5.6 0.6 1.5 0.5
Neuregulin 4 (Nrg4) 1.8 n.s. 1.4 9.1 1.3 0.2
Epidermal growth factor (Egf) 0.6 5.1 1.3 ns 4.6 0.6
Serum/glucocorticoid regulated kinase (Sgk) 1.5 n.s. 2.2 0.6 1.9 0.1
G protein-coupled receptor kinase 5 (Grk5) 1.5 n.s. 0.9 ns 2.9 0.1
Cell cycle
emerin 0.6 4.2 1.1 0.6 0.5 3.5
cyclin-dependent kinase inhibitor 1A p21 (cdkn1a) 2.3 1.7 3 0.6 2.7 2
B-cell translocation gene 2, anti-proliferative (Btg2) 1.3 ns 2.2 0.6 1.6 7
BCL2-like (Bcl2I1) 1.7 1.7 3.2 0.6 2.2 2.7
growth arrest and DNA-damage-inducible 45 γ (Gadd45g) 1.3 ns 1.7 0.6 1.9 1.5
FDR: false discovery rate (%), FDR > 10 = not significant (ns).
and B cell translocation (Bcl2l1), reached significance in
doxorubicin-treated animals (Table 2). Therefore, cellular
apoptosis was comparatively examined by TUNEL reaction
in cardiac sections from mice of 1 month and 3 months
of age. Increased cell death was observed in doxorubicin-
treated hearts with an average of 0.35 ± 0.2 TUNEL(+)
nuclei per field of 0.2 mm2, which was similar in WTD
and KOD (Figure S1, Supplementary Material, available
at doi:10.5402/2012/745185), apoptosis was rare or nil in
nontreated WT and KO [6]. The presence of the active Cas-
pase 3 protein was monitored in whole ventricular extracts
by western blotting (Figure S1 supplemental), showing a
significant increased ratio to GAPDH in WTD samples, yet,
at a low level relative to a positive control of staurosporin-
treated cardiomyocytes in culture. The cellular apoptosis
was therefore significant in WTD hearts as monitored by
the higher expression of apoptotic-related genes, TUNEL(+)
cells and the significant increase protein level of caspase 3
(Figure 4). Consistent with the induced apoptosis in WTD,
genes related to oxidative stress (Nfkbia, Atf4, Map3k6, Mnk2,
Mkp, Dnaja1, Gadd45g) were significantly represented in
WTD hearts (Table SI, supplemental). The expression of heat
shock protein 70 (hsp1a) reached the highest level in WTD,
in agreement with oxidative stress conditions [15].
3.7. Gene Expression Profile in Exacerbated Cytotoxicity
3.7.1. Growth Factor Expression Profile. A deregulated cy-
tokine profile was significant in the erbB4-KOD, which
included the downregulation of natriuretic peptide recep-
tor, angiotensin-like receptor and the upregulation of IL-
2 associated to stress and inflammatory responses [16].
Most remarkable was the significant imbalanced expression
of a cohort of key cardiac growth factors (e.g., Egf, Hb-
egf, Ptn, Posn, Gcdnf, Fgf1, Igf-I) that underlined the
erbB4-KOD (Table 3). The overexpression of Hb-egf was
statistically significant in WTD and KOD mice, with a
significant upregulation of Egf in KOD (Table 3), associated
to pathological forms of hypertrophy [13, 17, 18]. In
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Table 3: Deregulated expression of growth factor and IGF-I pathway genes. Deregulated expression of growth factor genes underlines erbB4-
KOD hearts by the upregulation of Egf, Hb-egf, Ptn, Post and downregulation of Fgf1 and IgfI. Comparative expression of genes related to
the IGF-I pathway exhibits an extended downregulation in erbB4-KOD relative to KO hearts. Abbreviations: phosphatidylinositol 3-hydroxi
kinase (PI30-K); murine thymoma viral oncogene homolog 2 serine/threonine protein kinase (Akt2). Statistically significant data correspond
to fold change ratios at FDR < 10, ns: not significant.
Gene Genebank
ErbB4-KO WTD ErbB4-KOD
ratio FDR ratio FDR ratio FDR
Growth factors
Fibroblast growth factor 1 (Fgf1) AA261582 0.6 4.9 1.0 ns 0.7 14
Glial cell derived neurotrophic factor (Gdnf) W45748 1.3 ns 1.8 5.3 1.3 ns
Gndf receptor 3 (Gdnra3) AA050083 2.0 2.0 1.1 ns 1.6 2.0
Epidermal growth factor (Egf) AI326499 0.6 5.0 1.3 ns 4.6 0.6
Egf-fibulin-like extracellular matrix (Efemp) AI156278 0.7 9.5 0.7 ns 6.4 8.9
Heparin binding-Egf (Hbegf) AI595201 1.4 ns 4.6 0.6 4.5 9.4
Pleiotrophin (Ptn) AI047160 1.0 ns 2.6 ns 4.5 0.5
Secreted frizzled-related (Srfp) AI019575 1.0 ns 1.2 ns 2.0 0.7
Periostin, osteoblastic factor (Postn) W81878 1.5 3.5 0.9 ns 1.5 1.5
Insulin-like growth factor-I (Igf1) AI604642 0.7 ns 1.1 ns 0.35 0.2
IGF-I signaling
Insulin-like growth factor-I (Igf1) AA822429 0.75 16 1.1 ns 0.52 0.2
Insulin-like growth factor-I (Igf1) AI604642 0.74 15 1.1 ns 0.35 0.1
Igf1 binding protein 1 (Igfbp1) AI892189 1.2 n.s. 1.0 ns 0.55 0.1
PI 30K regulatory subunit p85 beta (Pik3r1) AA033042 0.8 n.s. 0.8 ns 0.32 0.1
serine/threonine protein kinase (Akt2) AA437947 0.7 5.07 0.9 ns 0.58 0.1
FDR: false discovery rate (%), FDR > 10 = not significant (ns).
Table 4: Deregulation of ubiquitin-proteasome system genes. Comparative expression levels among the three models. Upregulation of
Ubiquitin ligase, associated regulatory genes and deregulation of related proteases are significant in erbB4-KOD. Significant data correspond
to fold change ratios at FDR < 10, ns: not significant.
Gene Genebank
ErbB4-KO WTD ErbB4-KOD
ratio FDR ratio FDR ratio FDR
Ubiquitin-Proteasome system
Ubiquitin-conjugating enzyme 5 (Ubc5 homolog) AA517487 1.1 ns 0.9 ns 5.6 0.5
Casitas B-lineage lymphoma b (Cblb) AI430293 1.0 ns 1.8 0.9 2.2 2.1
Autophagy-related 4A-like (Atg4a homolog) AI048074 0.9 ns 1.0 ns 2.0 0.2
LON peptidase (lonp) AA241939 0.8 ns 1.6 9.1 2.0 0.5
Ubiquitin ligase complex component (Ubr) AA615286 1.5 6.9 2.2 0.6 1.8 1.7
Carboxypeptidase X 2 M14 family (Cpxm2) AA690480 1.4 ns 1.6 0.9 1.7 0.8
Ubiquitin-regulatory protein (Nsfl1c) AW2095992 0.7 4.9 0.9 ns 1.5 0.7
Ubiquitin-like 1 (sentrin) activating enzyme subunit 1 (Sae1) AI604685 1.0 ns 1.0 ns 0.6 2.5
Proteasome beta 9 (multifunctional protease 2) (Psmb9) AA822485 1.0 ns 0.6 5.2 0.7 0.1
FDR: false discovery rate (%), FDR > 10 = not significant (ns).
contrast, the insulin-like growth factor-I (IGF-I), implicated
in physiological hypertrophy [19], was downregulated in
the knockouts, exhibiting a severe decay in erbB4-KOD
with the compromised expression of molecules of the
PI30-kinase complex (Table 3). Growth factors regulated by
IGF-I, that is, hepatic growth factor (Hgf ) and vascular
endothelial growth factor C (Vegfc) exhibited a signifi-
cant 40% decay. An additional list contains other highly
significantly up or down regulated genes of Wt versus
erbB4-KOD, not discussed in this manuscript (Table SII,
supplemental).
3.7.2. Ubiquitin-Proteasome System. looseness=1 Concur-
rent to a requirement for the local activity of IGF-I in the
prevention of ubiquitin-mediated muscle atrophy [20], the
decay of IGF-I in erbB4-KOD is accompanied by the deregu-
lation of a relevant set of genes of the ubiquitin-proteasome
system in erbB4-KOD. The remarkable upregulation of
inducible related-ligase genes and the deregulation (up or
down) of associated proteases (Table 4) in erbB4-KOD hearts
may result in an abnormal protein homeostasis. To eval-
uate the biological incidence of the deregulated ubiquitin-

































































































Figure 2: Cardiac contractility assay. Left ventricular developed
pressure (LVDP, mm Hg) was determined in isolated hearts from
WTD (n = 4) and KOD (n = 4) compared to WT (n = 5)
and KO (n = 5) mice of both genders at the age of 3 months.
Isoproterenol induced a significant increase in LVDP (a) A lower
LVDP was registered in WTD and KOD relative to corresponding
WT and KO. Half relaxation time (t1/2) was similar among the three
conditions relative to WT. Values are average ± SEM, ∗P < 0.05.
performed immunostaining assays by employing antibodies
against ubiquitin in cardiac sections from mice at the
age of 1 and 3 months (Figure 5). Ubiquitin (+) protein
aggregates were found exacerbated in KOD cardiomyocytes
with an average of 2.4 ± 1.3 cardiomyocytes/0.2 mm2 versus
0.35 ± 0.3/0.2 mm2 in KO and 0.12 ± 0.08/0.2 mm2 in
WTD (Figure 6(a)). The potential cardiomyocyte damage as
a net result of the aggravated doxorubicin toxicity in the
erbB4-KOD was monitored by immunodetection of cardiac
troponin I (cTnI) serum levels. A remarkable increase in
cTnI was determined in KOD with an average of 14.5 ±
4.2 ng/mL, with intermediate levels in WTD and KO and
relative to the low or nil level in WT (Figure 6(b)).
Taken together, these results reveal a severe deregulation
of the ubiquitin-proteasome system with excessive protein
aggregation and cardiomyocyte damage with release of
cTnI, which underline the aggravated doxorubicin-toxicity in
erbB4-KOD hearts.
4. Discussion
Relevant evidence demonstrated the essential role of NRG-1
signaling through cognate erbB2/erbB4 heterodimers in the
heart, moreover, clinical data has revealed that an impaired
NRG-1 signaling potentiates the cardiotoxic effect of anthra-
cycline therapies. In this study, we examined severely affected
pathways in the ventricular-specific erbB4-KO at the age of
1 and 3 months following doxorubicin treatment that may
account for the exacerbated cardiotoxicity.
4.1. Hypertrophic Response to NRG-1/erbB4-Deficiency and
Doxorrubicin. Among major overexpressed group of genes,
the hypertrophy-related components were a commonality
among the three mouse conditions. Compared to WTD
hearts, characterized by a thinning of ventricular walls
with an unchanged heart-to-body weight ratio, the KOD
manifested an increase in the heart-to-body weight ratio
accompanied by an intermediate ANF level relative to
the highest and lowest ratios determined in the KO and
WTD, respectively. The erbB2-dependent mechanism was
represented by a large number of significantly deregulated
genes in erbB4-KOD, suggesting the contribution of this
pathway to the enlargement of the heart.
4.2. Cellular Apoptosis. The significant upregulation of
apoptotic-related genes together with the overexpression of
oxidative stress pathway components underlined the heart
condition of WTD mouse, which is in agreement with
published evidence [21, 22]. In WTD hearts, apoptotic
mechanisms were also found significantly active as mon-
itored by the increased level of active caspase 3 and the
presence of TUNEL(+) nuclei in cardiac sections. The KOD
manifested a similar level of TUNEL(+) cells relative to WTD
instead of an exacerbated mitochondrial-dependent toxicity
that could account for the aggravated cardiac remodeling of
KOD heart.
4.3. Growth Factor Disorder in KOD. In this study, we
have established a cohort of relevant growth factors, whose
imbalanced expression maybe overall associated to cardiac
remodeling disorders. In erbB4-KOD hearts, the severe
decay of IGF-I, required for physiological hypertrophic
remodeling, likely converge into the remarkable dilation and
thinning of ventricular walls with heterogeneous cardiomy-
ocyte population of an abnormal length. Relative to adult
KOD, the decay in the IGF-I mRNA level as determined by
qRT-PCR was found similarly low in KOD at 1 month of age.
In this regard, the IGF-I expression profile maybe relevant
to NRG-1 impaired activities in remodeling rather than to a

















































Figure 3: Validation of cDNA microarray ratios and functional clustering. The cDNA array ratios were correlated to RT-PCR ratios
of differentially expressed genes. (a) Following logarithmic transformation, RT-PCR ratios were plotted against cDNA array ratios. (b)
Differentially expressed genes among erbB4-KO, WTD, and erbB4-KOD hearts using the criteria of FDR < 10 were enriched in GO terms
and functionally clustered. The graphics represent top groups enriched in number of genes and expression fold change corresponding to
























Figure 4: Cellular level of Caspase 3. The active caspase 3 (17 kD)
level was determined by Western blots from ventricular extracts of 1
and 3 months treated and nontreated WT and KO and normalized
against GAPDH. The caspase 3/GAPDH ratios were plotted as
average ± SD (n = 4).
In addition to the individual activities as powerful
enhancers of muscle growth, both NRG-1 and IGF-I have
been proven to synergize activities for both cardiomyocyte
proliferation and myofibrillogenesis through PI30-kinse/Akt
and Ras-MAPK pathways respectively, in ex vivo models and
in cultured cells [23]. In this context, it is suggested that
growth factor interactions may also modulate the dominant
proliferative or differentiating activities of the factors per se.
In a similar setting to erbB4-KOD mice, the induced
doxorubicin-cardiotoxicity in NRG-1 heterozygous mice
leads to a decreased activation of Akt and MAPK pathways
[24].
4.4. Ubiquitin-Proteasome System Deregulation Mediates
Homeostasis Block in KOD. Recently, a role for PPARα/IGF-
I, downregulated in KOD, has been suggested to con-
form a cardioprotective axis against cell damage during
ischemia and hemodynamic conditions [25], as well local
IGF-I activity was demonstrated to prevent the activation
of the ubiquitin-proteasome pathway in failing human
hearts [20, 26]. In the erbB4-KOD, components of the
ubiquitin-proteasome system were found severely deregu-
lated with the overexpression of critical regulators, such
as inducible ubiquitin-ligase enzymes [27], and the up-
or downregulation of related proteases. In this regard,
the deregulation of the ubiquitin-proteasome system, likely
linked to the decay in IGF-I/PI30-kinase, represents a main
functional group synergistically affected in the erbB4-KOD
heart.
The number of cardiomyoctes affected by large protein
aggregates in erbB4-KOD represented a 7-fold increase
relative to the number of erbB4-KO cardiomyocytes with a
similar ubiquitinated profile, indicating excessive autophagic
vacuolization in KOD. In this regard, protein ubiquitination
is recognized to exert a dual role in both cardioprotec-







Figure 5: Protein ubiquination in cardiomyocytes. Transverse ventricular sections of nontreated WT and KO and doxorubicin-treated WT
and KO hearts (WTD, KOD) (n = 4) were immunnostained with antibodies against ubiquitin, revealed with biotin-coupled antiolyclonal
rabbit and FITC-coupled streptavidin (green). The membrane was stained with wheat germ agglutinin (TRICT-coupled WGA, red) and
nuclei with DAPI (blue). The images were scanned with fluorescent microscope (upper panel), original magnification 400x. Scale bar:
100 μm. Note ubiquitin-protein aggregates (arrows) and ubiquitin-labeled proteins adjacent to the membrane in erbB4-KOD. Detailed
images of KOD sections with large ubiquitin-posistive protein aggregates were obtained by confocal microscopy (lower panel).
death was revealed by the appearance of large ubiquitin-
positive protein aggregates [30, 31], named autophagic
vacuolization according to recent nomenclature recom-
mendations [32]. Autophagic vacuolization has been also
suggested to be useful predictor of myocardial deterioration
[33].
In KOD mice, cardiomyocyte damage was indicated by
the significant increase in serum levels of cardiac troponin
I. Interestingly, this result agrees with human patient data
suggesting that cTnI serum level is a sensitive cardiotoxic
marker for patients following trastuzumab and doxorubicin
therapy [34, 35].
In summary, these results extend our current knowl-
edge by demonstrating that the response of erbB4-KO
heart to doxorubicin toxicity has a net result in excessive
autophagic vacuolization, consistent with the association
of an abnormal protein homeostasis with severe cardiac
disorders.
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Figure 6: Cardiomyocyte Autophagic Vacuolization and release of
cTnI. (a) Cardiomyocytes exhibiting large ubiquitinated protein
aggregates (arrow) from images as shown in Figure 5 were counted
in consecutive fields of 0.2 mm2 from cardiac section of nontreated
and doxorubicin-treated 1 month and 3 months WT and KO hearts
(WTD, KOD) (n = 4). The average values ± SD were plotted
with a significant number of ubiquitin (+) cardiomyocytes in KOD,
∗∗P < 0.01. (b) The release of cTnI was determined in whole serum
from WT, KO, WTD, and KOD mice (n = 4), the average values ±
SD were plotted (n = 4), ∗∗P < 0.001.
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